Spatial genomics market seen topping $1.76 billion by 2030

The Business Research Company projects the spatial genomics market will grow from $0.72 billion in 2025 to $0.86 billion in 2026, then reach $1.76 billion by 2030. The report points to precision medicine, AI analysis and multiomics adoption as key drivers, with North America leading and Asia-Pacific expected to grow fastest.

Why it matters: - Spatial genomics is moving from a research niche to a core tool for studying disease in tissue context. - The technology could improve biomarker discovery, personalized therapy design and drug development workflows. - The market’s projected growth signals rising demand across academic, clinical and biopharma settings.

What happened: - The Business Research Company released its Spatial Genomics Global Market Report 2026, covering market size, trends and a forecast through 2035. - The report says the spatial genomics market will grow from $0.72 billion in 2025 to $0.86 billion in 2026. - The report projects the market will reach $1.76 billion by 2030. - The company lists North America as the largest regional market in 2025. - The company expects Asia-Pacific to post the fastest growth over the forecast period. - The report includes coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - The market is expected to grow at a 20.0% compound annual growth rate in 2026. - The report forecasts a 19.5% compound annual growth rate through 2030. - Growth to date has been driven by next-generation sequencing adoption, precision medicine research, genomics funding at academic institutions, more molecular biology labs and more cancer research. - The report says future growth will be supported by AI-powered spatial genomics analysis, demand for personalized medicine and targeted therapies, broader multiomics adoption, cloud-based biomedical data infrastructure and spatial biology use in drug discovery. - The report highlights spatial multiomics for fine-scale tissue mapping across disease studies. - The report points to growing use of spatial transcriptomics in oncology and neuroscience. - The report also cites broader use of AI-driven bioinformatics, cloud genomic data storage and imaging-sequencing integration. - Spatial genomics lets scientists map gene activity inside the physical context of cells and tissues. - The approach combines sequencing, molecular profiling and imaging to preserve location-specific data that traditional genomic methods can miss. - The technology helps researchers study cellular function, disease development and tissue structure. - Precision medicine is one of the main drivers behind market expansion. - Precision medicine tailors treatment to patient genetics, biomarkers and disease characteristics. - The Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in the U.S. in 2023, up from six in 2022.

Between the lines: - The report suggests spatial genomics is benefiting from a broader shift toward more granular biological data and more targeted treatment development. - The combination of AI, cloud infrastructure and multiomics points to a market that is becoming more data-intensive and more collaborative. - North America’s lead and Asia-Pacific’s faster growth suggest an established research base in one region and expanding adoption in another.

What's next: - The report expects spatial genomics to keep gaining traction in disease research, oncology and neuroscience. - Wider use in drug discovery and personalized medicine could expand commercial demand through 2030. - The company says new analytical features in its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables.

The bottom line: - Spatial genomics is on a steep growth curve, and the report frames the field as a long-term beneficiary of precision medicine and AI-enabled analysis.